KOMZIFTI launch revenue of $5.8M in the first full quarter signals early commercial traction, but the stock will likely trade on upcoming clinical catalysts (EHA June 2026 data for ziftomenib/7+3, ASCO May 2026 darlifarnib data) rather than this quarter's financials. Monitor payer adoption trends and repeat prescription rates for signs of sustained uptake.
KURA drugs
KURA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $9.48entry
- T+1 · 6mo ago 0.00%α +0.00% · $9.48
- T+5 · 6mo ago −5.49%α −4.33% · $8.96
- T+20 · 5mo ago −6.54%α −5.93% · $8.86
- T+60 · 3mo ago +0.95%α −3.49% · $9.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology reported Q1 2026 results with $5.8M in KOMZIFTI product revenue (first full commercial quarter), beating consensus revenue estimates. However, the net loss widened to $73.3M ($0.83/share) vs $57.4M ($0.66/share) in Q1 2025, driven by increased R&D and SG&A costs for the commercial launch and clinical trials. The company maintains a strong cash position of $580.8M plus $180M in anticipated collaboration payments, funding operations into 2028.
Key Financial Metrics
Key Facts
- Q1 2026 net product revenue of $5.8M from KOMZIFTI, first full commercial quarter
- 85 new patient starts and 157 total prescriptions in Q1 2026
- Net loss of $73.3M ($0.83/share) vs $57.4M ($0.66/share) in Q1 2025
- Cash and investments of $580.8M as of March 31, 2026, down from $667.2M at year-end 2025
- R&D expenses of $65.3M, up from $56.0M in Q1 2025, driven by KOMET-017 Phase 3 trials
- SG&A expenses of $31.6M, up from $22.8M in Q1 2025, reflecting commercialization costs
- Payer coverage >93% across plans covering >12 million lives
- Multiple clinical data readouts expected in 2026 across AML combination settings
Financial Impact
Q1 2026 total revenue of $18.3M ($5.8M product + $12.5M collaboration) vs consensus $25.9M; net loss of $73.3M vs consensus loss of $77.0M (EPS $-0.83 vs consensus $-0.88, a 5.7% beat)
Risk Factors
- Cash burn rate of ~$86M/quarter implies ~6-7 quarters of runway without additional collaboration milestones
- Competition from other menin inhibitors (e.g., Syndax's revumenib) could limit market share
- Differentiation syndrome boxed warning may constrain prescriber adoption
- Phase 3 KOMET-017 trial results not expected until 2028, creating binary event risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-219422 |
| Document: kura-20260512.htm | 0001193125-26-219422 |
| Document: 0001193125-26-219422-index-headers.html | 0001193125-26-219422 |
| Document: 0001193125-26-219422-index.html | 0001193125-26-219422 |
| Document: 0001193125-26-219422.txt | 0001193125-26-219422 |
| 8-K Data (Synthetic) | 0001193125-26-219422 |
Track record
29 reports on KURA
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers